STOCK TITAN

[Form 4] Alzamend Neuro, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

TriMas Corp. (TRS) Form 144 filing discloses a proposed sale of 63,965 common shares—about 0.16 % of the 40.64 M shares outstanding—valued at roughly $2.24 M. The seller intends to execute the trade through Fidelity Brokerage Services on Nasdaq around 29 Jul 2025. All shares were acquired in 2021 via stock-option exercises and restricted-stock vesting; no prior sales were reported in the last three months. Form 144 is a notice, not an executed sale, but it signals potential insider liquidity activity. Given the small percentage of total shares, the transaction should have limited market impact unless accompanied by further disposals.

La dichiarazione Form 144 di TriMas Corp. (TRS) rivela una proposta di vendita di 63.965 azioni ordinarie, pari a circa lo 0,16% delle 40,64 milioni di azioni in circolazione, per un valore approssimativo di 2,24 milioni di dollari. Il venditore prevede di effettuare la transazione tramite Fidelity Brokerage Services sul Nasdaq intorno al 29 luglio 2025. Tutte le azioni sono state acquisite nel 2021 tramite esercizi di opzioni su azioni e maturazione di azioni vincolate; non sono state segnalate vendite precedenti negli ultimi tre mesi. Il modulo Form 144 è una comunicazione e non una vendita già eseguita, ma indica una possibile attività di liquidità da parte di insider. Considerata la piccola percentuale del totale delle azioni, la transazione dovrebbe avere un impatto limitato sul mercato, a meno che non venga accompagnata da ulteriori cessioni.

La presentación del Formulario 144 de TriMas Corp. (TRS) revela una propuesta de venta de 63,965 acciones comunes, aproximadamente el 0,16% de las 40.64 millones de acciones en circulación, valoradas en alrededor de 2.24 millones de dólares. El vendedor tiene la intención de realizar la operación a través de Fidelity Brokerage Services en Nasdaq alrededor del 29 de julio de 2025. Todas las acciones fueron adquiridas en 2021 mediante el ejercicio de opciones sobre acciones y la consolidación de acciones restringidas; no se reportaron ventas previas en los últimos tres meses. El Formulario 144 es un aviso, no una venta ejecutada, pero señala una posible actividad de liquidez interna. Dado el pequeño porcentaje del total de acciones, la transacción debería tener un impacto limitado en el mercado, a menos que se acompañe de disposiciones adicionales.

TriMas Corp. (TRS)의 Form 144 제출은 약 0.16%에 해당하는 63,965주의 보통주 매각 제안을 공개하며, 이는 총 4,064만 주 중 일부로 약 224만 달러의 가치가 있습니다. 판매자는 2025년 7월 29일경 Nasdaq에서 Fidelity Brokerage Services를 통해 거래를 실행할 예정입니다. 모든 주식은 2021년에 주식 옵션 행사 및 제한 주식 권리 확정으로 취득되었으며, 지난 3개월 동안 이전 판매는 보고되지 않았습니다. Form 144는 통지서로서 실제 매각이 이루어진 것은 아니지만 내부자 유동성 활동 가능성을 나타냅니다. 전체 주식의 적은 비율을 고려할 때, 추가 매각이 수반되지 않는 한 이번 거래는 시장에 미치는 영향이 제한적일 것으로 보입니다.

Le dépôt du formulaire 144 de TriMas Corp. (TRS) révèle une proposition de vente de 63 965 actions ordinaires, soit environ 0,16 % des 40,64 millions d’actions en circulation, pour une valeur d’environ 2,24 millions de dollars. Le vendeur prévoit d’exécuter la transaction via Fidelity Brokerage Services sur le Nasdaq aux alentours du 29 juillet 2025. Toutes les actions ont été acquises en 2021 par l’exercice d’options d’achat d’actions et la levée de restrictions sur des actions bloquées ; aucune vente antérieure n’a été signalée au cours des trois derniers mois. Le formulaire 144 est un avis, et non une vente réalisée, mais il indique une possible activité de liquidité d’initiés. Étant donné la faible proportion du total des actions, la transaction devrait avoir un impact limité sur le marché, sauf en cas de cessions supplémentaires.

Die Form 144-Meldung von TriMas Corp. (TRS) offenbart einen geplanten Verkauf von 63.965 Stammaktien – etwa 0,16 % der 40,64 Millionen ausstehenden Aktien – mit einem Wert von rund 2,24 Millionen US-Dollar. Der Verkäufer beabsichtigt, den Handel über Fidelity Brokerage Services an der Nasdaq um den 29. Juli 2025 durchzuführen. Alle Aktien wurden 2021 durch Ausübung von Aktienoptionen und die Freigabe von beschränkten Aktien erworben; in den letzten drei Monaten wurden keine vorherigen Verkäufe gemeldet. Das Formular 144 ist eine Mitteilung und kein ausgeführter Verkauf, signalisiert jedoch potenzielle Insider-Liquiditätsaktivitäten. Aufgrund des geringen Anteils an den Gesamtaktien sollte die Transaktion begrenzte Marktauswirkungen haben, sofern sie nicht von weiteren Veräußerungen begleitet wird.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Modest insider sale (~0.16% of float); unlikely to move TRS shares materially.

Form 144 filings highlight insider intent rather than completed trades. Here, 63.9 k shares worth $2.24 M are slated for sale—insignificant versus TriMas’ 40.6 M shares outstanding and typical daily volume. The stock was acquired through routine equity-comp programs in 2021, suggesting profit-taking rather than deterioration in fundamentals. Absence of other recent sales reduces aggregation risk under Rule 144(e). Overall, I view the filing as neutral; investors should monitor additional filings to gauge broader insider sentiment.

La dichiarazione Form 144 di TriMas Corp. (TRS) rivela una proposta di vendita di 63.965 azioni ordinarie, pari a circa lo 0,16% delle 40,64 milioni di azioni in circolazione, per un valore approssimativo di 2,24 milioni di dollari. Il venditore prevede di effettuare la transazione tramite Fidelity Brokerage Services sul Nasdaq intorno al 29 luglio 2025. Tutte le azioni sono state acquisite nel 2021 tramite esercizi di opzioni su azioni e maturazione di azioni vincolate; non sono state segnalate vendite precedenti negli ultimi tre mesi. Il modulo Form 144 è una comunicazione e non una vendita già eseguita, ma indica una possibile attività di liquidità da parte di insider. Considerata la piccola percentuale del totale delle azioni, la transazione dovrebbe avere un impatto limitato sul mercato, a meno che non venga accompagnata da ulteriori cessioni.

La presentación del Formulario 144 de TriMas Corp. (TRS) revela una propuesta de venta de 63,965 acciones comunes, aproximadamente el 0,16% de las 40.64 millones de acciones en circulación, valoradas en alrededor de 2.24 millones de dólares. El vendedor tiene la intención de realizar la operación a través de Fidelity Brokerage Services en Nasdaq alrededor del 29 de julio de 2025. Todas las acciones fueron adquiridas en 2021 mediante el ejercicio de opciones sobre acciones y la consolidación de acciones restringidas; no se reportaron ventas previas en los últimos tres meses. El Formulario 144 es un aviso, no una venta ejecutada, pero señala una posible actividad de liquidez interna. Dado el pequeño porcentaje del total de acciones, la transacción debería tener un impacto limitado en el mercado, a menos que se acompañe de disposiciones adicionales.

TriMas Corp. (TRS)의 Form 144 제출은 약 0.16%에 해당하는 63,965주의 보통주 매각 제안을 공개하며, 이는 총 4,064만 주 중 일부로 약 224만 달러의 가치가 있습니다. 판매자는 2025년 7월 29일경 Nasdaq에서 Fidelity Brokerage Services를 통해 거래를 실행할 예정입니다. 모든 주식은 2021년에 주식 옵션 행사 및 제한 주식 권리 확정으로 취득되었으며, 지난 3개월 동안 이전 판매는 보고되지 않았습니다. Form 144는 통지서로서 실제 매각이 이루어진 것은 아니지만 내부자 유동성 활동 가능성을 나타냅니다. 전체 주식의 적은 비율을 고려할 때, 추가 매각이 수반되지 않는 한 이번 거래는 시장에 미치는 영향이 제한적일 것으로 보입니다.

Le dépôt du formulaire 144 de TriMas Corp. (TRS) révèle une proposition de vente de 63 965 actions ordinaires, soit environ 0,16 % des 40,64 millions d’actions en circulation, pour une valeur d’environ 2,24 millions de dollars. Le vendeur prévoit d’exécuter la transaction via Fidelity Brokerage Services sur le Nasdaq aux alentours du 29 juillet 2025. Toutes les actions ont été acquises en 2021 par l’exercice d’options d’achat d’actions et la levée de restrictions sur des actions bloquées ; aucune vente antérieure n’a été signalée au cours des trois derniers mois. Le formulaire 144 est un avis, et non une vente réalisée, mais il indique une possible activité de liquidité d’initiés. Étant donné la faible proportion du total des actions, la transaction devrait avoir un impact limité sur le marché, sauf en cas de cessions supplémentaires.

Die Form 144-Meldung von TriMas Corp. (TRS) offenbart einen geplanten Verkauf von 63.965 Stammaktien – etwa 0,16 % der 40,64 Millionen ausstehenden Aktien – mit einem Wert von rund 2,24 Millionen US-Dollar. Der Verkäufer beabsichtigt, den Handel über Fidelity Brokerage Services an der Nasdaq um den 29. Juli 2025 durchzuführen. Alle Aktien wurden 2021 durch Ausübung von Aktienoptionen und die Freigabe von beschränkten Aktien erworben; in den letzten drei Monaten wurden keine vorherigen Verkäufe gemeldet. Das Formular 144 ist eine Mitteilung und kein ausgeführter Verkauf, signalisiert jedoch potenzielle Insider-Liquiditätsaktivitäten. Aufgrund des geringen Anteils an den Gesamtaktien sollte die Transaktion begrenzte Marktauswirkungen haben, sofern sie nicht von weiteren Veräußerungen begleitet wird.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
AULT MILTON C III

(Last) (First) (Middle)
11411 SOUTHERN HIGHLANDS PARKWAY
SUITE 190

(Street)
LAS VEGAS NV 89141

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Alzamend Neuro, Inc. [ ALZN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/25/2025 S 36,532 D $2.8976(1) 46,020 I By Ault Lending, LLC(2)
Common Stock 07/28/2025 S 8,311 D $2.6849 37,709 I By Ault Lending, LLC(2)
Common Stock 1,843 D
Common Stock 11,068 I By Ault Life Sciences, Inc.(3)
Common Stock 61 I By Ault Life Sciences Fund, LLC(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sale price of $2.8976. The range of sales prices on the transaction date was $2.891 to $2.9129 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
2. Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Hyperscale Data, Inc. ("HSD"). Mr. Ault, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending.
3. Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc.
4. Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.
Remarks:
/s/ Milton C. Ault, III 07/29/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Alzamend Neuro Inc

NASDAQ:ALZN

ALZN Rankings

ALZN Latest News

ALZN Latest SEC Filings

ALZN Stock Data

7.30M
2.87M
3.09%
1.72%
3.46%
Biotechnology
Pharmaceutical Preparations
Link
United States
ATLANTA